Assessment of Serum Catestatin Level in Acne Vulgaris Patients
Assessment of Serum Catestatin Level in Acne Vulgaris Patients Before and After Treatment With Oral Isotretinoin
Aswan University
60 participants
Jan 10, 2025
INTERVENTIONAL
Summary
Acne vulgaris is a persistent inflammatory condition of the pilosebaceous unit, affecting 85% of people between the ages of 12 and 24, it is regarded as one of the most common diseases in teenagers and young adults. Catestatin, a peptide derived from chromogranin A (CgA), was first discovered in 1997 as an acute nicotinic-cholinergic antagonist. Later, it was determined that CST is a pleiotropic hormone.
Eligibility
Inclusion Criteria1
- Healthy persons of both sexes with moderate and severe acne.
Exclusion Criteria11
- Pregnant and lactating women.
- Immunocompromised patients.
- Severe anemia.
- History of chronic liver disease.
- Hyperlipidemia
- Non-inflammatory acne conditions.
- History of neurologic disorders.
- History of neoplastic disorders.
- History of cardiac disease.
- History of systemic acne treatment for at least 4 weeks prior to inclusion and no topical treatments for at least 2 weeks.
- Cases with known hypersensitivity reaction to isotretinoin.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
* Measure the serum levels of catestatin in patients with moderate and severe acne vulgaris versus healthy control persons. * Evaluate the effect of oral isotretinoin treatment on serum catestatin levels in patients with moderate and severe acne vulgaris.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07054398